X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209526
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210823
https://www.clinicaltrialsarena.com/news/sanofi-multiple-myeloma-trial/
https://www.prnewswire.com/news-releases/halozyme-announces-janssen-receives-us-fda-approval-of-darzalex-faspro-daratumumab-and-hyaluronidase-fihj-in-combination-with-carfilzomib-and-dexamethasone-for-patients-with-multiple-myeloma-after-first-or-subsequent-relapse-301435510.html
https://seekingalpha.com/news/3752261-health-canada-approves-sanofis-sarclisa-combination-for-multiple-myeloma
https://www.biospace.com/article/releases/breckenridge-announces-approval-of-its-anda-for-carfilzomib-intravenous-powder-generic-for-kyprolis-/?s=74#:~:text=BERLIN%2C%20Conn.%2C%20June%2016,(generic%20for%20Kyprolis%C2%AE).
https://www.prnewswire.com/news-releases/breckenridge-announces-approval-of-its-anda-for-carfilzomib-intravenous-powder-generic-for-kyprolis-301313999.html
https://www.business-standard.com/article/news-cm/natco-receives-usfda-approval-for-carfilzomib-vials-anda-121061500236_1.html#:~:text=Natco%20Pharma%20announce%20that%20its,and%20Drug%20Administration%20(USFDA).
http://www.pharmatimes.com/news/ec_approves_new_sarclisa_indication_1367395
http://www.pharmatimes.com/news/nice_recommends_kyprolis_triple_combination_treatment_for_multiple_myeloma_1365629
https://www.raps.org/news-and-articles/news-articles/2020/8/fda-roundup-kyprolis-kesimpta-cystadrops
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-carfilzomib-and-daratumumab-dexamethasone-multiple-myeloma
https://endpts.com/jj-adds-yet-another-multiple-myeloma-regimen-to-the-darzalex-label-as-sanofi-rival-jumps-in/
http://www.pharmatimes.com/news/us_expand_use_of_janssens_darzalex_1347150
https://ir.genmab.com/news-releases/news-release-details/genmab-announces-plan-transition-arzerrar-ofatumumab-oncology#:~:text=Copenhagen%2C%20Denmark%3B%20August%2020%2C,U.S.%20This%20program%20will%20be
https://www.sanofi.com/en/media-room/press-releases/2020/2020-06-02-15-00-00
https://www.oncolyticsbiotech.com/press-releases/detail/507/oncolytics-biotech-presents-clinical-proof-of-concept
https://www.fiercepharma.com/marketing/sanofi-takes-aim-at-j-j-s-myeloma-star-darzalex-latest-sarclisa-trial-win
https://www.prnewswire.com/news-releases/oncolytics-biotech-announces-publication-of-abstracts-at-the-2020-american-society-of-clinical-oncology-virtual-annual-meeting-301059108.html
https://www.bloomberg.com/news/articles/2020-05-05/amgen-wins-ruling-on-patents-for-kyprolis-cancer-drug
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211185
https://www.amgen.com/media/news-releases/2020/01/amgen-commences-strategic-collaboration-with-beigene-to-expand-oncology-presence-in-china/
https://endpts.com/amgen-takes-a-2-7b-stake-in-beigene-gaining-a-prominent-ally-in-china-to-help-seize-a-leading-role-in-cancer-drug-commercialization-and-development/
https://www.fiercepharma.com/pharma/amgen-s-kyprolis-j-j-s-darzalex-team-up-myeloma-survival-win
https://www.prnewswire.com/news-releases/amgen-announces-phase-3-candor-study-combining-kyprolis-carfilzomib-and-darzalex-daratumumab-meets-primary-endpoint-of-progression-free-survival-300917706.html
https://www.fiercebiotech.com/biotech/amgen-shares-hit-after-analysts-expose-buried-fda-trial-halt
https://www.gov.uk/drug-safety-update/carfilzomib-kyprolis-reminder-of-risk-of-potentially-fatal-cardiac-events
https://www.biopharmadive.com/news/meet-the-protein-responsible-for-nearly-100b-in-cancer-drug-deals/561097/
https://www.fiercepharma.com/marketing/karyopharm-s-xpovio-nabs-multiple-myeloma-nod-despite-checkered-past-but-5th-line?utm_source=internal&utm_medium=rss
https://www.fiercebiotech.com/biotech/asco-sanofi-s-anti-cd38-combo-boosts-responses-extends-lives-advanced-multiple-myeloma
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/natco-onyx-settle-cancer-drug-patent-litigation/articleshow/69591844.cms
https://www.fiercepharma.com/pharma/mass-exodus-amgen-sales-reps-sparks-legal-battle-karyopharm-over-rival-multiple-myeloma
https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/UCM293268.pdf
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-challenge-of-carfilzomib-10-mgvial-kyprolis-202714-for-injection-1545895266.pdf
https://www.ema.europa.eu/documents/procedural-steps-after/kyprolis-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
https://www.fiercepharma.com/pharma/could-amgen-soften-neulasta-biosimilar-blow-alexion-buy
https://www.prnewswire.com/news-releases/fda-approves-addition-of-positive-overall-survival-data-from-phase-3-aspire-trial-to-kyprolis-carfilzomib-label-300663855.html
https://www.prnewswire.com/news-releases/phase-3-arrow-interim-analysis-shows-once-weekly-70-mgm2-kyprolis-carfilzomib-regimen-significantly-extended-progression-free-survival-versus-a-twice-weekly-27-mgm2-regimen-in-patients-with-relapsed-and-refractory-multip-300658409.html
https://www.prnewswire.com/news-releases/amgen-receives-positive-chmp-opinion-to-add-overall-survival-results-from-the-phase-3-aspire-study-to-kyprolis-carfilzomib-label-300638636.html
https://www.pharmacompass.com/pdf/news/kyprolis-carfilzomib-onyx-therapeutics-v-cipla-limited-1525071239.pdf
https://www.pharmacompass.com/pdf/news/kyprolis-carfilzomibonyx-therapeutics-inc-v-breckenridge-pharmaceutical-1520247305.pdf
http://www.pmlive.com/pharma_news/amgen_set_for_kyprolis_label_boost_after_chmp_backing_1219727
https://www.prnewswire.com/news-releases/amgen-receives-chmp-positive-opinion-to-add-updated-overall-survival-data-to-kyprolis-carfilzomib-label-300589994.html
https://www.pharmacompass.com/pdf/news/kyprolis-carfilzomib-onyx-therapeutics-v-apotex-1517228367.pdf
https://www.fiercepharma.com/pharma/amgen-kicks-off-2018-double-good-news-for-slow-growing-kyprolis
https://cen.acs.org/articles/96/i2/Carfilzomib-linked-higher-rates-cardiovascular.html
https://www.reuters.com/article/us-amgen-study/amgens-kyprolis-improves-overall-survival-in-blood-cancer-patients-idUSKBN1E52MX
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-challenge-of-kyprolis-carfilzomib-injection-1512710626.pdf
Market Place
Share 
